Select a medication above to begin.
Elahere (mirvetuximab soravtansine-gynx)
mirvetuximab soravtansine
Black Box Warnings .
Ocular Toxicity
incl. visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis; withhold for toxicity until improvement, then resume at the same or reduced dose; permanently D/C tx if Grade 4 toxicity; ophthalmic exam incl. visual acuity and slit lamp exam, before tx start, then every other cycle x8 cycles, then as clinically indicated; admin. prophylactic artificial tears and ophthalmic topical steroids during tx
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = mirvetuximab soravtansine-gynx
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
folate receptor alpha-positive ovarian CA, platinum-resistant
- [6 mg/kg/dose IV x1 on day 1 of 21-day cycle]
- Info: for pts w/ epithelial ovarian, fallopian tube, or primary peritoneal CA who have received 1-3 lines of tx; use adjusted wt of IBW + 0.4 x (ABW - IBW) for dose calculation; see pkg insert for detailed eye care requirement before, during and after infusion
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin >1.5x ULN: avoid use
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.